title: Concerns in the development of an assay for determination of a highly conjugated adsorption-prone compound in human urine.
abstract: Concerns in pre-analytical handling of urine samples are discussed using a new KDR kinase inhibitor, 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one (compound A), as an example of a case where high light sensitivity and low analyte recovery (high affinity for container surface) were found. The absence of these problems in plasma samples may be a result of the plasma protein content. Low recovery of the analyte from urine can be remedied by either changing the container or by using additives, such as bovine serum albumin (BSA) or non-ionic surfactant Tween-20. In the case of compound A, changing containers (polypropylene versus glass vial) or addition of BSA did bring analyte recovery up to 80%. However, the addition of 0.2% Tween-20 into urine quality controls (QCs) gave more than 95% analyte recovery, indicating effective reduction of analyte loss to the surface of containers. The urine assay using mixed-mode SPE and LC-MS/MS was not affected significantly by introducing Tween-20 into the samples. The mean SPE extraction recovery was 68.4% and matrix suppression of ionization on MS was less than 8% at all analyte concentrations. The linear range of the calibration curve was 0.5-400 ng/mL on PE Sciex API 3000 LC-MS/MS system. The assay intraday accuracy and precision were 92.1-104.8% and <4.2% (%CV), respectively. Urine QC samples, containing 0.2% Tween-20, gave excellent recovery after three cycles of freeze and thaw. Since analyte loss to its urine container surface is not unique to compound A (M. Schwartz, W. Kline, B. Matuszewski, Anal. Chim. Acta 352 (1997) 299-307; A.L. Fisher, E. DePuy, T. Shih, R. Stearns, Y. Lee, K. Gottesdiener, S. Flattery, M. De Smet, B. Keymeulen, D.G. Musson, J. Pharm. Biomed. Anal. 26 (2001) 739-752), we suggest an evaluation of the potential problem in the early stages of urine assay development to ensure reliable quantitation of analytes. The addition of Tween-20 can serve as a useful analytical tool to other analytes with similar situations.
authors.affiliation: Merck Research Laboratories, WP75A-303, West Point, PA 19486, USA. yang_xu@merck.com
authors.forename: Yang
authors.initials: Y
authors.lastname: Xu
authors.forename: Lihong
authors.initials: L
authors.lastname: Du
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Rose
authors.forename: Irong
authors.initials: I
authors.lastname: Fu
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Woolf
authors.forename: Donald G
authors.initials: DG
authors.lastname: Musson
mesh_terms: D000327:Adsorption; D002851:Chromatography, High Pressure Liquid / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D010879:Piperazines / Q000097:blood / Q000528:radiation effects / Q000652:urine*; D011136:Polysorbates; D047428:Protein Kinase Inhibitors / Q000097:blood / Q000528:radiation effects / Q000652:urine*; D011786:Quality Control; D015363:Quinolones / Q000097:blood / Q000528:radiation effects / Q000652:urine*; D015203:Reproducibility of Results; D012710:Serum Albumin, Bovine; D013048:Specimen Handling; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods; D014466:Ultraviolet Rays; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors*
chemical_list: D010879:Piperazines; D011136:Polysorbates; D047428:Protein Kinase Inhibitors; D015363:Quinolones; D012710:Serum Albumin, Bovine; D040301:Vascular Endothelial Growth Factor Receptor-2; C501378:3-(5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl)-1H-quinolin-2-one